(Reuters) – Aveo Pharmaceuticals Inc said it was informed by its partner Astellas Pharma Inc that the Japanese company would not be seeking marketing approval for their experimental kidney cancer drug in Europe. Aveo’s shares were down about 13 percent in extended trade, after closing at $2.70 on the Nasdaq. Astellas does not intend to fund any future studies of the drug, tivozanib, in renal cell cancer, Aveo said in a regulatory filing on Thursday. (http://r.reuters.com/caz38t) Earlier this month, an advisory panel to the U.S. …
Read more here: Aveo says partner Astellas will not seek EU nod for kidney cancer drug


